Vertex (VRTX) Slumps on VX-809 Data Presentation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Analyst Says Vertex (VRTX) Drug Data Shows "At Least Moderate Impact"
October 12, 2012 8:29 AM EDTVertex Pharmaceuticals (Nasdaq: VRTX) presented additional data from cohort 2 of the Phase 2 VX-809 (lumacaftor/ivacaftor) trial in F508del cystic fibrosis patients at the NACFC meeting yesterday.
Commenting on the data, analyst Alan Carr of Needham and Company said "Although interpretation... More
